• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Diseases
chagas disease icon

Chagas disease

Symptoms, transmission, and current treatments for Chagas disease

Home > Diseases
chagas disease icon

Chagas disease

Symptoms, transmission, and current treatments for Chagas disease

  • Overview
  • Facts
  • Projects & achievements
  • Target product profiles

What is Chagas disease? 

Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening disease caused by the parasite Trypanosoma cruzi. It is most commonly transmitted by biting insects known as ‘kissing bugs’ that are infected with the parasite. As people typically show no symptoms for many years, most are unaware they have Chagas.

Up to a third of people with Chagas will suffer heart damage that becomes evident only many years later and can lead to progressive heart failure or sudden death. Chagas kills more people in Latin America each year than any other parasitic disease, including malaria.

What is the impact of Chagas disease?

  • Over 7 million people estimated to have Chagas in the world
  • Over 100 million people at risk
  • 30,000-40,000 new cases per year
  • Over 10,000 deaths per year
  • Less than 10% of those infected have been diagnosed
  • Endemic in 21 countries across Latin America
  • Also present in North America, Europe, Japan, and Australia

ENDEMIC IN 21 LATIN AMERICAN COUNTRIES

What are current treatments for Chagas disease?

The two current treatments, benznidazole and nifurtimox, were both discovered half a century ago.

They are effective against the disease if given soon after infection and appear to be effective in the chronic asymptomatic phase of the disease. However, they have significant drawbacks, including:

  • long treatment periods (60-90 days)
  • serious side effects
  • a high drop-out rate of patients due to side effects
  • they have not been proven effective in people with severe chronic symptoms

To improve treatment in the short and medium-term, we are investigating new regimens of benznidazole to reduce side effects, and, together with partners, we have helped develop the first form of benznidazole specifically for children.

What new treatments for Chagas disease are needed?

Chagas disease has been targeted by the World Health Organization (WHO) for elimination but fewer than 10% of people with Chagas have been diagnosed and even fewer have been treated. To eliminate the disease, we need a new drug for both chronic stages of the disease that is safe, efficacious, and adapted to the field. Access to treatment and diagnostics also needs to be greatly expanded. We also need to identify better biomarkers, to measure the impact of treatment and predict who is at risk for developing severe symptoms.

What Chagas disease medicines are we working on?

We aim to deliver new, safer, more affordable and effective treatments for people affected by Chagas disease. We are also focused on improving access to diagnosis and treatment using existing tools.

Find out about our work developing treatments for Chagas disease

How do you get Chagas disease?

  • Insect bites: triatomine bugs, commonly known as kissing bugs, transmit the T. cruzi parasites by biting people and defecating or urinating close by; the parasites enter the body when people unintentionally scratch the area, allowing the parasites in the faeces or urine to enter the bite
  • Mother-to-child: transmission from mother to child during pregnancy or childbirth
  • Blood transfusion or organ transplant: this type of transmission has decreased in the last decade because of improved control in blood banks and hospitals
  • Food: eating food contaminated with infected kissing bugs or their faeces

What are the symptoms of Chagas disease?

The disease has two clinical phases:

Acute phase:

  • Lasts for about 2-8 weeks after infection
  • Can occasionally cause severe symptoms or deaths, especially in infants
  • In most cases, symptoms are absent or mild and unspecific
  • Possible skin lesions or a purplish swelling of the lids of one eye
  • Possible fever, headache, enlarged lymph glands, pallor, muscle pain, difficulty in breathing, swelling, and abdominal or chest pain

Chronic phase, which can be divided into two stages:

  • The chronic, indeterminate stage is when people have no symptoms. This stage lasts for the rest of the infected person’s life unless they are treated. During this stage, the parasite is hidden deep in organ tissue (especially the heart).
  • The advanced chronic stage is when 30-40% of people with Chagas experience symptoms. This stage develops years after infection and most often results in damage to the heart, while others may experience abnormal enlargement of the colon or esophagus.
  • People in both chronic stages are at risk for severe symptoms if their immune system is suppressed due to medical treatment or immune disorders such as HIV.

How is Chagas disease diagnosed?

Suspected cases of acute Chagas are confirmed by detecting parasites in the blood through a microscope. In the chronic phase, when the vast majority of people are tested, the parasite is difficult to detect. Healthcare providers instead test blood for antibodies, which are produced by the body to fight the disease. Because no test is sufficiently accurate to work as a stand-alone, two or three different tests must be used. A lack of easy, straightforward testing in most settings is one of the major barriers that prevents people from starting treatment. After treatment, it takes many years for current tests to show as “negative”. A better test of cure is another important need.

Find out about our work on biomarkers

More information

  • WHO factsheet 

Last updated April 2025

Early diagnosis and treatment can save millions of lives

Many people with Chagas disease spend their whole lives unaware they have it.
READ MORE

Making medical history for neglected patients

We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them

Young boy sitting on a hospital bed being examined by a nurse

Chagas disease

Causes heart and vital organ damage, after people are bitten by blood-sucking bugs

We delivered the first-ever treatment for children; now we’re searching for new drug candidates and working to boost access to care

Patient medical examination

Cryptococcal meningitis

Without treatment, deadly for thousands of people with advanced HIV

We’re working to improve access to life-saving treatments and developing an easier-to-use formulation

Girl with skin lesions on her nose

Cutaneous leishmaniasis

Leaves disfiguring, life-long scars that lead to severe social stigma

We’re working to develop safer, shorter treatments for this disabling disease

Doctor with young patient in hospital setting

Dengue

Rapidly spreading climate-sensitive disease with no specific treatment

We’re building a global partnership with dengue-endemic countries to develop a first treatment

Father walking in rural village with a cane and holding his son's hand

Filaria: river blindness

Lead to unbearable itching, disfiguring skin lesions, and even blindness

We’re working to develop a safe, effective, and affordable drug for the prevention and treatment of this debilitating disease

Young man standing in the street

Hepatitis C

Millions are left without treatment even though effective drugs exist

We’ve delivered a treatment as simple, safe, and effective as the best drugs available today – at a fraction of the cost 

Woman standing in front of her door house in a rural village in Sudan

Mycetoma

Often ends in amputation​, after people get infected from stepping on a thorn

We conducted the world’s first trial for an alternative to current treatments, which are toxic and difficult to administer

Mother holding her baby in her arms smiling

Paediatric HIV

Without treatment, half of children die before their second birthday

We’ve developed a strawberry-flavoured treatment to meet the needs of children long neglected by the global HIV response

Healthcare workers in a hospital

Pandemic Preparedness

The COVID-19 pandemic intensified global health inequalities

We’re bringing together partners and accelerating research to prepare for future viral pandemics in low-resource settings

Doctor diagnosing a man in a village with his hands on the man's neck

Sleeping sickness

Transmitted by the bite of a tsetse fly and causes severe neurological disorders

We delivered a revolutionary new drug to replace toxic treatments, and have ongoing trials to eliminate this disease

Girl looking over a fence

Visceral leishmaniasis

Is one of the world’s biggest parasitic killers, spread by the bites of sandflies

We’re working to develop a new generation of treatments to replace drugs that are painful, ineffective, and cause side effects

Chagas disease

Cryptococcal meningitis

Cutaneous leishmaniasis

Dengue

Filaria: river blindness

Hepatitis C

Mycetoma

Paediatric HIV

Pandemic Preparedness

Sleeping sickness

Visceral leishmaniasis

VIEW ALL DISEASES

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License